Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Alkermes (ALKS) Research & Development (2016 - 2026)

Alkermes has reported Research & Development over the past 16 years, most recently at $93.0 million for Q4 2025.

  • Quarterly Research & Development rose 59.93% to $93.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $324.0 million through Dec 2025, up 32.05% year-over-year, with the annual reading at $324.0 million for FY2025, 32.05% up from the prior year.
  • Research & Development was $93.0 million for Q4 2025 at Alkermes, up from $81.7 million in the prior quarter.
  • Over five years, Research & Development peaked at $118.4 million in Q3 2021 and troughed at -$17.2 million in Q4 2021.
  • The 5-year median for Research & Development is $72.9 million (2023), against an average of $70.2 million.
  • Year-over-year, Research & Development crashed 115.37% in 2021 and then surged 546.62% in 2023.
  • A 5-year view of Research & Development shows it stood at -$17.2 million in 2021, then increased by 3.91% to -$16.6 million in 2022, then surged by 546.62% to $73.9 million in 2023, then fell by 21.32% to $58.2 million in 2024, then skyrocketed by 59.93% to $93.0 million in 2025.
  • Per Business Quant, the three most recent readings for ALKS's Research & Development are $93.0 million (Q4 2025), $81.7 million (Q3 2025), and $77.4 million (Q2 2025).